Our novel therapy for eliminating cancer tumors, MFA370, will be tested in clinical trials on metastatic bladder cancer. Preclinical studies have shown positive results in inducing cell death in breast, colorectal and prostate cancer cells too. MFA370 is planned to be a simple oral tablet with few if any side effects. It is a combination of two safe, standard, well-established pharmaceuticals that have already undergone large-scale clinical trials.